Early breast cancer: Diagnosis, treatment and survivorship

British Journal of Nursing

Volumn 21, Issue 17 SUPPL., 2012, Pages

  Meade, Elizabeth ^a   Dowling, Maura ^b  

^a Tullamore General Hospital   (Ireland)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Breast cancer; Molecular profiling; Specialist breast care nurse; Survivorship; Treatment options

Indexed keywords

EID: 84866896387     PISSN: 09660461     EISSN: None     Source Type: Journal    
DOI: 10.12968/bjon.2012.21.sup17.s4     Document Type: Article

References (48)

1. Abe O, Abe R, Asaishi K et al; Early Breast Cancer Trialists' Collaborative Group (1995) Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med 333(22): 1444-55
2. Andersson Y, de Boniface J, Jönsson PE et al (2012) Axillary recurrence rate 5 years after negative sentinel node biopsy for breast cancer. Br J Surg 99(2) 226-31. EPub 2011.
3. Autier P, Boniol M, La Vecchia C et al (2010) Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ 341: c3620
4. Ballinger R, Ford E, Pennery E, Jenkins V, Ring A, Fallowfield L (2012) Specialist breast care and research nurses' attitudes to adjuvant chemotherapy in older women with breast cancer. Eur J Oncol Nurs 16(1): 78-86. EPub 2011.
5. Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC (2009) Early breast cancer. Lancet 373(9673): 1463-79
6. Benitez PR, Keisch ME, Vicini F et al (2007) Five-year results: the initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer. Am J Surg 194(4): 456-62
7. Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353(17): 1784-92
8. Bonilla L, Ben-Aharon I, Vidal L, Gafter-Gvili A, Leibovici L, Stemmer SM (2010) Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst 102(24): 1845-54. EPub.
9. Bradley CJ, Given CW, Roberts C (2002) Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst 94(7)490-6
10. Brown R, Butow P, Wilson-Genderson M, Bernhard J, Ribi K, Juraskova I (2012) Meeting the decision-making preferences of patients with breast cancer in oncology consultations: impact on decision-related outcomes. J Clin Oncol 30(8): 857-62. Epub.
11. Burstein HJ, Prestrud AA, Seidenfeld J et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28(23): 3784-96. EPub.
12. Burstein HJ, Piccart-Gebhart MJ, Perez EA et al (2012) Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol 30(18): 2179-82. Epub.
13. Clayton MF, Dudley WN (2009): Patient-centered communication during oncology follow-up visits for breast cancer survivors: content and temporal structure. Oncol Nurs Forum 36(2): E68-79
14. Cox K, Wilson E. (2003) Follow-up for people with cancer: nurse-led services and telephone interventions. J Adv Nurs 43(1): 51-61
15. Darby S, McGale P, Correa C et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804): 1707-16. Epub.
16. Davies C, Godwin J, Gray R et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793): 771-84
17. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2008)
18. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20): 1938-48
19. Gianni L, Norton L, Wolmark N, Suter TM, Bonadonna G, Hortobagyi GN (2009) Role of anthracyclines in the treatment of early breast cancer. J Clin Oncol 27(28): 4798-808. Epub.
20. Hayes DF (2012) Targeting adjuvant chemotherapy: a good idea that needs to be proven! J Clin Oncol 30(12): 1264-7. Epub.
21. Howard-Anderson J, Ganz PA, Bower JE, Stanton AL (2012) Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 104(5): 386-405. Epub.
22. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2): 69-90. Epub.
23. Jones HA, Antonini N, Hart AA et al (2009) Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol 27(3): 4939-47. Epub.
24. Kelly KM, Dean J, Comulada WS, Lee SJ (2010) Breast cancer detection using automated whole breast ultrasound and mammography in radiographically dense breasts. Eur Radiol 20(3): 734-42. Epub 2009
25. Khatcheressian JL, Wolff AC, Smith TJ et al; American Society of Clinical Oncology (2006) American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 24(31): 5091-7. Epub.
26. Kimman ML, Dirksen CD, Voogd AC et al (2011) Nurse-led telephone follow-up and an educational group programme after breast cancer treatment: results of a 2 × 2 randomised controlled trial. Eur J Cancer 47(7): 1027-36. EPub.
27. Koinberg IL, Fridlund B, Engholm GB, Holmberg L (2004) Nurse-led follow-up on demand or by a physician after breast cancer surgery: a randomised study. Eur J Oncol Nurs 8(2): 109-17
28. Kwan W, Jackson J, Weir LM, Dingee C, McGregor G, Olivotto IA (2002) Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life. J Clin Oncol 20(20): 4242-8
29. Langer I, Guller U, Berclaz G et al (2007) Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients. Ann Surg 245(3): 452-61
30. Li CI, Daling JR, Porter PL, Tang MTC, Malone KE (2009) Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer. J Clin Oncol 27(32): 5312-8
31. Lim M, Bellon JR, Gelman R et al (2006) A prospective study of conservative surgery without radiation therapy in select patients with Stage I breast cancer.Int J Radiat Oncol Biol Phys 65(4): 1149-54. EPub.
32. Mayer EL, Gropper AB, Neville BA et al (2012) Breast cancer survivors' perceptions of survivorship care options. J Clin Oncol 30(2): 158-63. Epub 2011.
33. Mouridsen H, Giobbie-Hurder A, Goldhirsch A et al BIG 1-98 Collaborative Group (2009) Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361(8): 766-76
34. National Comprehensive Cancer Network (2012) NCCN Guideline Version 1. Invasive Breast Cancer. NCCN, Fort Washington.
35. National Institute for Health and Clinical Excellence (2009) Early and locally advanced breast cancer. Diagnosis and treatment. Guideline 80. www.nice.org.uk/CG80
36. National Institute for Health and Clinical Excellence (2012) Breast cancer (early & locally advanced) (CG80). http://www.nice.org.uk/CG80 (accessed 14 September 2012)
37. Nelson HD, Zakher B, Cantor A et al (2012) Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med 156(9): 635-48
38. Oeffinger KC, McCabe MS (2006) Models for delivering survivorship care. J Clin Oncol 24(32): 5117-24
39. Park CC, Mitsumori M, Nixon A et al (2000) Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J Clin Oncol 18(8): 1668-75
40. Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26(15): 2568-81
41. Ravdin PM, Cronin KA, Howlader N et al (2007) The decrease in breastcancer incidence in 2003 in the United States. N Engl J Med 356(16): 1670-4
42. Reis-Filho JS & Pusztai L (2011): Gene expression profiling in breast cancer: Classification, prognostication, and prediction. Lancet 378(9805): 1812-23
43. Rock CL, Demark-Wahnefried W (2002) Nutrition and survival after the diagnosis of breast cancer: A review of the evidence. J Clin Oncol 20(15): 3302-16
44. Slamon D, Eiermann W, Robert N et al; Breast Cancer International Research Group (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14): 1273-83
45. Veronesi U, Salvadori B, luini A, et al (1995) Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1,973 patients. Eur J Cancer 31A(10) 1574-9
46. Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G (2005) Breast cancer. Lancet 365(9472): 1727-41
47. Veronesi U, Viale G, Paganelli G et al (2010) Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg 251(4): 595-600
48. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28(10): 1684-91. Epub.